Abstract: The present invention provides for a library of vectors comprising human HC-CDR3 regions of varying length, wherein the diversity of said library is focused on the HC-CDR3 region only and diversity has been optimized such that redundancy is reduced for short HC-CDR3 loops and coverage of HC-CDR3 region variants for longer loop lengths has been increased. The library of the present invention is displayed on phage for selection against target antigens.

Abstract: The present invention relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof to a patient in need of such a treatment. The invention further relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof in combination with one or more additional anti-inflammatory active agents to a patient in need of such a treatment.

Abstract: The present invention relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof to a patient in need of such a treatment. The invention further relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof in combination with one or more additional anti-inflammatory active agents to a patient in need of such a treatment.

Abstract: Compound selected from 4-(2(S)-benzoylamino-3-naphthalen-2-yl-propionylamino)-N-hydroxy-benzamide and benzo[1,3]dioxole-5-carboxylic acid [1(S)-(4-hydroxycarbamoyl-phenylcarbamoyl)-2-naphthalen-2-yl-ethyl]-amide, for use in the treatment of a HIV infection. The compound is administered in combination and/or in temporal proximity with at least one anti-retroviral agent.

Abstract: The present invention refers to an iron (III) caseinsuccinylate characterised by a content of iron comprised between 4.5% and 7% by weight, and by a solubility in water approximately greater than 92%. The present invention further refers to a method for preparing iron (III) caseinsuccinylate.

Abstract: Method of treating a tumor in a patient in need thereof by administering to the patient an effective amount of 4-[6-(diethylaminomethyl)naphth-2-ylmethyloxycarbamoyl]benzohydrozamic acid.

Abstract: The present invention relates to the use of estriol in the preparation of a pharmaceutical formulation for vaginal administration with the capacity to self-limit the absorption of estriol, for the prevention and/or the treatment of urogenital atrophy in women said women having a high probability of suffering from a cardiovascular pathology or suffering or having suffered from a cardiovascular pathology.

Abstract: The present invention relates to the use of estriol in the preparation of a pharmaceutical formulation for vaginal administration with the capacity to self-limit the absorption of estriol, for the prevention and/or the treatment of urogenital atrophy in women, said women having a high probability of developing an estrogen-dependent tumor or suffering or having suffered from an estrogen-dependent tumor.

Abstract: The invention relates to formulations of hydrophilic substances encapsulated in liposomes, to the method of encapsulation of the hydrophilic substances in the liposomes and the use of said formulations in the prevention and/or treatment of diseases and/or disorders in humans and animals.

Abstract: The invention relates to the use of low doses of estriol by vaginal route for treatment and/or prevention of urogenital atrophy due to estrogen deficit in women.

Abstract: The invention relates to the use of derivatives of sulphonic acid (I) or one of the pharmaceutically-acceptable prodrugs or salts thereof in the preparation of a medicament for the treatment of vasoproliferative ocular diseases, said sulphonic acid having formula (I).

Abstract: A naphthalenesulfonic acid or quinolinesulfonic acid of formula (I), wherein A is N or a CR8 formula group, where R8 is H, OH, NR10OR11, independently from one another, where R10 and R11 represent H or C1-C6 alkyl or a group of formula NH—CO—R12, where R12 is C1-C6 alkyl or C6-C10 aryl; R1 and R2 represent H or SO3R9, independently from one another, where R9 is H, ammonium or a cation of an alkali or alkaline-earth metal; R3 is H or OH; and R4, R5, R6 and R7 represent H, an NR10R11 or NH—CO—R12 group, independently from one another; on the condition that (i) at least one of R1 or R2 is SO3R9, and (ii) at least one of R4, R5, R6 or R7 is an NR10R11 or NH—CO—R12 group, or their pharmaceutically acceptable salts; and a pharmaceutically acceptable excipient.

Abstract: The invention relates to oral pharmaceutical compositions which take the form of orally-dispersible tablets containing calcium and, optionally, vitamin D and/or fluorine together with pharmaceutically-acceptable excipients and which can be used for the treatment or prevention of osteoporosis and other diseases characterised by loss of bone mass.

Abstract: The invention relates to a method for preparing liposomes with at least two uniformly distributed phospholipids without using organic solvents.

Abstract: The invention relates to formulations of hydrophilic substances encapsulated in liposomes, to the method of encapsulation of the hydrophilic substances in the liposomes and the use of said formulations in the prevention and/or treatment of diseases and/or disorders in humans and animals.

Abstract: Stable, biologically compatible pharmaceutical compositions in the form of water-in-oil microemulsions (w/o), for the sustained release by parenteral administration of active ingredients which are hydrophilic or are made hydrophilic by suitable derivatization, a process for the preparation of said microemulsions and the use thereof.

Abstract: Complexes of paroxetine, as free base or salt, with a cyclodextrin or a cyclodextrin derivative having a molar ratio between paroxetine and cyclodextrin ranging from 1:0.25 to 1:20, suitable for use in liquid and solid pharmaceutical compositions for oral and parenteral administration.

Abstract: The present invention relates to oligopeptide derived from fragments of the C-reactive protein (CRP), and to their use in the therapy of cardiovascular and inflammatory diseases.

Abstract: Heparin derivatives are disclosed that may be used to inhibit formation of metastases. One series of heparin derivatives of the invention are N-acylated with monocarboxylic acids or dicarboxylic acids and have molecular weights from about 1000 Daltons to about 30,000 Daltons. Another series of heparin derivatives of the invention have average molecular weights ranging from about 1000 to 3000 daltons, and are optionally N-acylated with residues from aliphatic monocarboxylic or dicarboxylic acids.

Abstract: Oligopeptides derived from fragments of C-reactive proteins and their use as immunomodulating agents in the therapy of cardiovascular and inflammatory diseases.